Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Features

Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology

Michael O'Riordan

March 03, 2020

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Features

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Yael L. Maxwell

November 27, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

Advertisement

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Roughly 80% of ESC Guideline Writers Have Financial COIs

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Top News in Coronary Artery Disease: 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

The Bioresorbable Stent Story So Far: What Promise? What Price?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content